Back to top
more

Anavex Life Sciences (AVXL)

(Real Time Quote from BATS)

$3.42 USD

3.42
662,474

+0.01 (0.29%)

Updated Apr 25, 2024 01:51 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Protagonist (PTGX) Up 14% on Licensing Deal With Takeda

by Zacks Equity Research

Per the deal, Protagonist (PTGX) will grant exclusive rights to Takeda to market its late-stage rare hematology drug. In return, Takeda will make an upfront payment of $300 million.

Vertex's (VRTX) Non-Opioid Pain Drug Meets Primary Goal

by Zacks Equity Research

Three late-stage studies data show that Vertex's (VRTX) experimental non-opioid drug reduced pain across a 48-hour period. Based on this data, VRTX intends to submit an FDA filing by mid-2024.

GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance

by Zacks Equity Research

GSK's revenues benefit from strong growth across all segments, especially the Shingles and RSV vaccines. The company also issues fresh 2024 guidance for all its segments.

Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 530.68%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 530.7% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

New Strong Buy Stocks for January 31st

by Zacks Equity Research

ADMA, IKT, YPF, AVXL and EKSO have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.

New Strong Buy Stocks for January 26th

by Zacks Equity Research

IKT, EGO, MDB, PD and AVXL have been added to the Zacks Rank #1 (Strong Buy) List on January 26, 2023.

Anavex Life Sciences (AVXL) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

New Strong Buy Stocks for January 24th

by Zacks Equity Research

ADMA, PBPB, YPF, CM and AVXL have been added to the Zacks Rank #1 (Strong Buy) List on January 24, 2023.

Anavex (AVXL): Strong Industry, Solid Earnings Estimate Revisions

by Zacks Equity Research

Anavex (AVXL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Sweta Killa headshot

5 Small-Cap Stocks to Play the January Effect

by Sweta Killa

Anavex Life Sciences (AVXL), Peakstone Realty Trust (PKST), AC Immune (ACIU), Getaround (GETR) and Akoya Biosciences (AKYA) could be solid picks to play the January Effect.

Anavex (AVXL) Falls 35% on Mixed Rett Syndrome Study Results

by Zacks Equity Research

Anavex (AVXL) falls 35% on mixed results from the mid to late-stage study of 30 mg ANAVEX2-73 for the treatment of pediatric Rett Syndrome patients aged 5-17 years.

Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAA

by Zacks Equity Research

The CHMP agrees that Anavex's (AVXL) blarcamesine for Alzheimer's disease is eligible for submission for a Union Marketing Authorisation in the EU. Shares rise.

Does Anavex Life Sciences (AVXL) Have the Potential to Rally 401.47% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 401.5% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 468.83% Upside in Anavex Life Sciences (AVXL): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Anavex Life Sciences (AVXL) points to a 468.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Anavex (AVXL) Up 12% on Regulatory Update for Alzheimer's Drug

by Zacks Equity Research

Anavex (AVXL) announces an encouraging regulatory update for its investigational candidate, blarcamesine, in the treatment of Alzheimer's disease. The stock rises 12%.

Is Anavex Life Sciences (AVXL) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Anavex Life Sciences (AVXL) and Clene Inc. (CLNN) have performed compared to their sector so far this year.

Wall Street Analysts Think Anavex Life Sciences (AVXL) Could Surge 338.45%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 338.5% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 342.31%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 342.3% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Here's Why You Should Add Acadia (ACAD) Stock to Your Portfolio

by Zacks Equity Research

Acadia (ACAD), a top-ranked stock at present, is witnessing steady growth in Nuplazid sales since its launch. The newly approved drug, Daybue, is set to provide an incremental stream of revenues.

Acadia (ACAD) Gets FDA Approval for Daybue for Rett Syndrome

by Zacks Equity Research

Acadia Therapeutics (ACAD) announces the FDA approval of its Rett Syndrome drug, trofinetide, for the treatment of adult and pediatric patients two years of age and older. Going to be marketed as Daybue in the United States.

Does Anavex Life Sciences (AVXL) Have the Potential to Rally 270.28% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Anavex Life Sciences (AVXL) points to a 270.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

FDA Rejects Accelerated Nod to Lilly's (LLY) Alzheimer's Drug

by Zacks Equity Research

The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.

Anavex's (AVXL) Lead Alzheimer's Drug Meets Study Goal

by Zacks Equity Research

Top-line data from a phase IIb/III study shows that Anave's (AVXL) lead drug exhibited statistical and clinical improvement in cognition and function in patients with early Alzheimer's disease.

Wall Street Analysts Think Anavex Life Sciences (AVXL) Could Surge 179%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 179.5% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Why Endo (ENDP) Stock Wilted After its Surge on Tuesday?

by Zacks Equity Research

Endo International (ENDO) tanks 26%, cooling off after its massive stock price surge on Tuesday, post the Supreme Court's decision to overturn Roe v. Wade.